COMMUNIQUÉS West-GlobeNewswire

DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2023
08/03/2024
Montrouge, France, le 8 mars 2024 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2023 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
08/03/2024
CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & [...]
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
08/03/2024
WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards [...]
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
08/03/2024
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop a first-of-its-kind [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
08/03/2024
Please see enclosed pdf. Attachment 08032024_trading_in_shares_LRA
Teladoc Health to Participate in Upcoming Investor Conference
08/03/2024
PURCHASE, NY, March 08, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief [...]
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
08/03/2024
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
08/03/2024
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity expected to [...]
MaNaDr's Weight Management Program Makes Waves at World Obesity Day Walk 2024 in Singapore
08/03/2024
SIngapore, March 08, 2024 (GLOBE NEWSWIRE) -- MaNaDr, a/k/a MOBILE-HEALTH NETWORK SOLUTIONS, a provider of comprehensive 24/7 telemedicine and healthcare products and services in the APAC region, today reported that the [...]
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
08/03/2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers NEWTOWN, Pa., March 08, 2024 (GLOBE [...]
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
08/03/2024
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
08/03/2024
Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood [...]
Olink announces change of date for Annual General Meeting
08/03/2024
UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19 th , 2024 [...]
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
08/03/2024
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark [...]
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
08/03/2024
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the [...]
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
08/03/2024
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September [...]
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
08/03/2024
Agency to convene an advisory committee to consider the drug WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly , announced today that the Food and Drug Administration (FDA) will convene an [...]
Arbutus to Participate in Two Upcoming Investor Conferences
08/03/2024
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
08/03/2024
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ( [...]

Pages